Clinical Study On Entecavir Combined With Matrine In HBeAg Positive Chronic Hepatitis B Treament

ObjectiveTo explor the clinical effects of Entecavir combine with Matrine in HBeAg positive chronic hepatitis B, to further increase the antiviral efficacy of entecavir.MethodsThe selected 96 patients were all from DongGuan Kanghua hospital from January 2014 to January 2015, who had been treated in outpatient and hospitalization with HBeAg positive chronic hepatitis B. The patients were divided into observation group and control group randomly,48 cases were included in each group. Both group were treated with entecavir tablets (made in Sino-American Shanghai squibb company, ETV.) 0.5mg each time, once a day. Patients in observation group are also provided with matrine (made in Jiangsu Zhengda tianqing pharmaceutical co., LTD.).2 pills each time, three times a day. Totally be treated for 24 weeks. Observe two groups of patients for 0、12 and 24weeks of ALT, HBV DNA quantification and conversion rate, HBsAg quantification and conversion rate, HBeAg conversion rate, HBeAg seroconversion rate. And these results were statistically analyzed compared between two groups of measurement data by using t-test; Count data comparison by chi-square test.ResultsCompare the result of treatment on the total efficiency of both the observation and control group in 12 weeks and 24 weeks, statistical analysis shows difference within the group(P<0.05). The total efficiency of observation group in 12 weeks and 24 weeks is 68.75% and 95.83% higher than 60.42% and 79.17% of control group obviously. Compare results before and in 12 weeks and 24 weeks after treatment within the group of the ALT quantification HBeAg quantification statistical were showed difference both the two group(P<0.05). Compare results in 12 weeks and 24 weeks after treatment within the group of the rate of ALT below the detection value、HBV DNA conversion rate、HBeAg conversion rate statistical were showed difference both the two group (P<0.05).When compared between the two groups for the ALT quantification in 12 weeks and 24 weeks after treatment, the statistical analysis shows difference (P<0.05), while compared within the two groups for HBeAg conversion rate、HBeAg/Anti-HBe seroconversion rate、the rate of ALT below the detection value aspects in 12 weeks and 24 weeks after treatment, the statistical analysis were showed no difference (P>0.05). Statistical analysis between the two groups of the total efficiency、HBsAg quantification、HBeAg quantification、 HBV DNA conversion rate, there was no difference in 12 weeks after treatment (P>0.05), While there was a statistical difference in 24 weeks after treatment (P<0.05)ConclusionEntecavir combine with Matrine has a good curative effect on HBeAg positive chronic hepatitis B, can improve patients related biochemical indicators significantly. For the conversion rate of HBV DNA, HBsAg quantification show a statistical difference and superiority in value compared with the single entecavir treatment. Although there was no statistical difference on HBeAg conversion rate, HBeAg/Anti-HBe seroconversion rate、the rate of ALT below the detection value between the two group, observation group shows superiority in value compared with the single entecavir group.